Positive results from trials of Bydureon (Amylin and Alkermes Inc) for Type 2 Diabetes

Results from an analysis of seven randomized clinical studies demonstrating that patients with Type 2 Diabetes treated with Bydureon (exenatide extended-release for injectable suspension), from Amylin and Alkermes Inc, experienced improvements in A1C, fasting glucose, weight and pulse pressure, regardless of baseline body weight. In the analysis more than 1,700 patients were stratified in quartiles by baseline body weight. Results showed that A1C reduction and weight loss were comparable across all quartiles (A1C: 1.4-1.5 percentage points; weight: 2.5-2.8 percent). A1C is a measure of average blood sugar over three months. The most common adverse event overall was hypoglycemia (16.4 percent). These findings are being presented at the 72nd Scientific Sessions of the American Diabetes Association. Bydureon was approved in the US in January 2012.